G-protein-coupled receptors (GPCRs) remain the primary conduit by which cells detect environmental stimuli and communicate with each other 1 . Upon activation by extracellular agonists, these seven-transmembrane-domain-containing receptors interact with heterotrimeric G proteins to regulate downstream second messenger and/or protein kinase cascades 1 . Crystallographic evidence from a prototypic GPCR, the β 2 -adrenergic receptor (β 2 AR), in complex with its cognate G protein, Gs, has provided a model for how agonist binding promotes conformational changes that propagate through the GPCR and into the nucleotide-binding pocket of the G protein α-subunit to catalyse GDP release, the key step required for GTP binding and activation of G proteins 2 . The structure also offers hints about how G-protein binding may, in turn, allosterically influence ligand binding. Here we provide functional evidence that G-protein coupling to the β 2 AR stabilizes a 'closed' receptor conformation characterized by restricted access to and egress from the hormone-binding site. Surprisingly, the effects of G protein on the hormone-binding site can be observed in the absence of a bound agonist, where G-protein coupling driven by basal receptor activity impedes the association of agonists, partial agonists, antagonists and inverse agonists. The ability of bound ligands to dissociate from the receptor is also hindered, providing a structural explanation for the G-protein-mediated enhancement of agonist affinity, which has been observed for many GPCR-G-protein pairs. Our data also indicate that, in contrast to agonist binding alone, coupling of a G protein in the absence of an agonist stabilizes large structural changes in a GPCR. The effects of nucleotide-free G protein on ligand-binding kinetics are shared by other members of the superfamily of GPCRs, suggesting that a common mechanism may underlie G-protein-mediated enhancement of agonist affinity.
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suggested that G-protein coupling enhances agonist affinity for the receptor, and can be abolished by uncoupling the G protein from the receptor with guanine nucleotides 7 . These and other data formed the basis for the ternary complex model of agonist-receptor-G-protein interactions 8, 9 . In this paradigm, the active state of the receptor is stabilized by both the agonist and G protein, and enhancement of agonist affinity arises owing to the positive cooperativity between agonist and G protein. However, using purified β 2 AR•Gs complexes, we observed peculiar binding characteristics of the antagonist [ 3 H]dihydroalprenolol ([ 3 H]DHAP) to β 2 AR (Fig. 1a ). As illustrated, addition of GDP increases the observed binding of a saturating concentration of [ 3 H] DHAP, whereas removal of GDP using a nucleotide lyase, apyrase, decreases [ 3 H]DHAP binding. The apyrase-mediated decrease in [ 3 H] DHAP binding is reversed upon addition of excess GDP, suggesting that the decrease is indeed due to the formation of nucleotide-free β 2 AR•Gs complexes. Removal of GDP from the β 2 AR•Gs complex relies on the constitutive activity of β 2 AR and the rapid hydrolysis (by apyrase) of GDP released from the α-subunit of Gs, Gsα. The nucleotide-free status of Gsα in these β 2 AR•Gs complexes was confirmed by rapid [ 35 S]GTPγS binding kinetics (Extended Data Fig. 1 Fig. 3 ). Thus, β 2 AR bound to nucleotide-free G protein adopts a conformation characterized by restricted access to the hormone-binding site. Crystallographic and pharmacological evidence suggests that the active conformation of the β 2 AR is stabilized by nucleotide-free Gs or by a single-chain camelid antibody raised against agonist-bound β 2 AR (nanobody Nb80) ( Fig. 2a) 2, 11, 12 . As illustrated in Fig. 2b (and Extended Data Fig. 4a ), Nb80 stabilizes a conformation of the β 2 AR that restricts [ 3 H]DHAP association, similar to nucleotide-free Gs. Importantly, Nb80 also slows the association of full agonist, [ 3 H]formoterol ( Fig. 2c ), as well as partial agonist, [ 3 H]CGP-12177 ( Fig. 2d ). These data suggest that in the nucleotide-free Gs-or Nb80stabilized active state, the β 2 AR adopts a closed conformation impairing access to the orthosteric ligand-binding site, regardless of the cooperativity of the orthosteric ligand with the G protein. These data are in line with our previous observation that the β-adrenergic receptor inverse agonist ICI-118,551 blocks the formation of β 2 AR•Gs complexes, but is unable to disrupt preformed complexes 10 . Nb80 also impairs binding of inverse agonist [ 3 H]carvedilol to the β 2 AR by modestly decreasing the observed association rate ( Fig. 2e ) but dramatically decreasing total binding, suggesting that Nb80 and [ 3 H] carvedilol do not simultaneously occupy β 2 AR.
Agonist-promoted G-protein engagement and subsequent nucleotide loss would be expected to stabilize the active, closed receptor conformation, thus trapping the agonist in the orthosteric site and enhancing its observed affinity. Indeed, uncoupling G protein from receptor using the GTP analogue GppNHp has been shown to accelerate agonist dissociation from the β 2 AR 13 . Such agonist-G-protein cooperativity is not predicted for neutral antagonists like alprenolol, which do not stimulate G-protein coupling and thus should not stabilize the closed conformation. However, we have previously demonstrated that Gs can be 'forced' to form a complex with the β 2 AR bound to the antagonist alprenolol 10 , provided that free nucleotide is removed, indicating that antagonist-bound β 2 AR retains enough basal activity to engage Gs. Consistent with this model, Fig. 2f and Extended Data Fig. 4b Analysis of access to the hormone-binding sites in inactive-and active-state β 2 AR structures provides a structural rationale for the slowing of agonist and antagonist association ( Fig 
and Supplementary Video 1). The binding of Gs or Nb80 to the β 2 AR stabilizes a rearrangement of the cytoplasmic end of transmembrane domain 7 (TM7; Fig. 4a , b) that is accompanied by changes immediately above the ligand-binding site, as well as a change in the structure of the extracellular loop (ECL) between TM4 and TM5 (ECL2). In comparison to the inactive β 2 AR, the structure of the β 2 AR-Gs or β 2 AR-Nb80 (or related Nb6B9) 14 complex identifies two aromatic residues, Phe193 (5.25 or ECL2) and Tyr308 7.35 , that move approximately 2-2.5 Å closer to each other to form a lid-like structure over the orthosteric ligand-binding site. Lys305 7.32 also contributes to capping the orthosteric site by trading its salt bridge 15 with Asp192 ECL2 for an interaction with the backbone carbonyl of Phe193 ECL2 (Fig. 4c ). These structural changes are stabilized in the active forms of β 2 AR bound to either the ultra-high-affinity agonist BI-167107 or the smaller, low-affinity agonist adrenaline 15 , and formation of this 'lid' would be expected to sterically obstruct both ligand association and dissociation.
To validate this structural model, we tested whether a residue smaller than tyrosine could modify the capacity of Nb80 to slow ligand association. Mutation of Tyr308 7.35 to alanine, previously shown to lower agonist affinity for the β 2 AR 16 , significantly diminishes the capacity of Nb80 to slow the association of [ 3 H]DHAP and even the agonist [ 3 H]formoterol (Extended Data Fig. 5 ), as suggested by recent molecular dynamics simulations 17 . Interestingly, and in contrast to [ 3 H]DHAP association, pre-incubation with 10 μM Nb80 also enhances the extent of [ 3 H]formoterol binding in the Y308A mutant. Eliminating barriers that impair access to the orthosteric site (for example, Y308A) allows the agonist to at least enter the receptor, where it can stabilize nanobody binding. The enhancement, therefore, is a reflection of the capacity of the agonist [ 3 H]formoterol to cooperatively stabilize Nb80 binding and vice versa, and concomitantly slow the dissociation of the bound agonist (Extended Data Fig. 5d ). The data also suggest that while Tyr308 7.35 markedly limits access to the orthosteric site, other residues may work in concert with Tyr308 7.35 in the active β 2 AR conformation to slow agonist dissociation.
It is noteworthy that the movement of Phe193 ECL2 and Tyr308 7.35 is not fully observed in the crystal structure of the β 2 AR bound to an agonist alone 18 , nor in the inactive-state structure of the β 1 AR bound to the agonist isoprenaline 19 (Extended Data Fig. 6 and Supplementary Videos 1, 2). Binding of G protein or G-protein mimetic (nanobody) is sufficient to stabilize the closed, active conformation since their effects on ligand-binding kinetics (as in Figs 1 and 2) are agonistindependent. An agonist may enhance G-protein engagement but poorly stabilizes the closed, active conformation by itself. Additionally, the data presented here suggest that formation of the closed, active conformation stabilized by the nucleotide-free G protein can occur owing to basal receptor activity, in keeping with predictions of more recent models of GPCR pharmacology such as the extended and cubic ternary complex models 20, 21 (see Supplementary Discussion). Moreover, conformational changes stabilized by the nucleotide-free G protein influence not only agonist binding, but ligand binding in general, implying that the role of nucleotides needs to be included in an updated version of ternary complex model. 
The capacity of G proteins to stabilize a closed receptor conformation explains the poorly defined GTPγS-mediated increase in radiolabelled antagonist binding observed with several GPCRs, including muscarinic, α-adrenergic, adenosine and opioid receptors [22] [23] [24] [25] (as in Extended Data Figs 7 and 8). We analysed the behaviour of the M2 muscarinic acetylcholine receptor (M2R) and the μ-opioid receptor (MOPr) to determine whether GTPγS-mediated uncoupling relieves a G-protein-stabilized closed conformation. We focused on these receptors since structural models are available for both inactive and active conformations [26] [27] [28] [29] , and to determine whether the mechanism we propose for the β 2 AR is shared among other GPCRs. The active-state structure of the M2R, in particular, revealed similar conformational changes to the β 2 AR in that a lid-like structure is formed above the orthosteric site 27 (see Supplementary Videos 4 and 5) . Although the structural changes are not identical, the effect of G proteins (or nanobodies) on the association and dissociation of ligands at the orthosteric sites is shared among the β 2 AR, M2R and MOPr (Extended Data Fig. 9 and Supplementary Video 3) , suggesting that the allosteric effects of G proteins on orthosteric agonists may be manifested by conceptually common mechanisms. More discussion of the details and implications can be found in Supplementary Discussion. Additionally, many recent studies have focused on the allosteric effect of sodium ions on class A GPCR ligand binding and signalling 30 . Outward movement of TM6 during receptor activation collapses the sodium-binding pocket in many class A GPCRs, thus it appears that loss of bound sodium is necessary for G proteins to stabilize a closed, active receptor conformation.
The formation of the closed conformation is also of particular interest for the development of allosteric modulators targeting class A GPCRs. Most allosteric-modulator-binding sites have focused on the extracellular vestibule located above the orthosteric ligand-binding sites. For the muscarinic M2R for example, the potent M2R allosteric positive modulator LY2119620 utilizes residues that form the lid in the active, closed conformation as described here, as the floor of the vestibule 27 . Stabilization of this closed conformation may therefore be an important aspect on the differentiation between positive allosteric modulators, which enhance agonist binding and activation, and negative allosteric modulators, which decrease agonist binding.
We provide pharmacological and biochemical evidence suggesting that the closed, active conformation of GPCRs is stabilized by the nucleotide-free G protein, allowing G proteins to influence passage of ligands to the orthosteric-binding site. The dramatic effect of G proteins on either ligand association or dissociation is consistent with, and in fact validates, structural models generated from X-ray crystallography in which G-protein coupling on the intracellular face of the receptor allosterically influences the structure of the extracellular face. Agonist or hormone binding enhances G-protein engagement, whereby formation of the active receptor conformation is accompanied by nucleotide loss from the G protein. Therefore, the capacity of G proteins to enhance agonist-binding affinity is structurally and energetically linked to the agonist's capacity to promote nucleotide loss from Gα.
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METHODS
Large-scale purification of the β 2 AR. β 2 AR bearing an N-terminal Flag tag and C-terminal 10×-His tag was expressed in Sf9 cells (Invitrogen) and purified as previously described 2 . Expression and purification of G protein and nanobodies. Gs and Go heterotrimer were expressed in HighFive (Invitrogen) insect cells using recombinant baculovirus and purified by chromatography on Ni-NTA, MonoQ, and Superdex 200 resin, as previously described 31 . Nanobodies were expressed in Escherichia coli and purified as previously described 11, 14, 27 . Membrane preparations. HEK293T cells (ATCC) were used for small-scale expression and purification of β 2 AR and mutants. Cells were grown in DMEM plus 10% FBS to ~70% confluency, then transfected with monomeric yellow fluorescent protein (mYFP)-β 2 AR (pCMV5, 6 μg DNA per 10-cm plate) using Lipofectamine 2000. Cells were harvested 40-48 h post-transfection in ice-cold lysis buffer buffer (50 mM HEPES, pH 8.0, 65 mM NaCl, 1 mM EDTA, 35 μg ml −1 phenylmethylsulfonyl fluoride, 32 μg ml −1 each tosyl-l-phenylalanine-chloromethylketone and tosyl-l-lysine-chloromethylketone, 3.2 μg ml −1 leupeptin, 3.2 μg ml −1 ovomucoid trypsin inhibitor). The cell suspension was sonicated using a Branson Sonifier and centrifuged for 20 min at 25,000g. The pellet was resuspended in wash buffer (50 mM HEPES, pH 8.0, 100 mM NaCl with protease inhibitors listed earlier) using a Dounce homogenizer, then centrifuged for 20 min at 25,000g. The pellet was resuspended and homogenized in minimal wash buffer and the volume was adjusted to reach a final protein concentration of 5 mg ml −1 as measured by the Bradford protein assay. Membranes were frozen by slowly pouring into liquid nitrogen and stored at −80 °C until use. Enrichment of β 2 AR and β 2 AR(Y308A) from HEK293T cells. Frozen membranes were thawed on ice and NaCl, MgCl 2 , and GTPγS were added to reach final concentrations of 300 mM, 1 mM and 10 μM, respectively. Timolol was then added to a final concentration of 1 μM and the membranes were incubated for 10 min on ice. Receptors were solubilized for 1 h at 4 °C in the presence of 1% dodecylmaltoside (DDM) and 0.1% cholesterol hemisuccinate (CHS). After centrifugation for 30 min at 25,000g, the supernatant was applied to Ni-NTA agarose. The column was slowly washed with 20 column volumes of 20 mM HEPES, pH 8.0, 300 mM NaCl, 0.1% DDM, 0.01% CHS to remove bound timolol. Receptor was eluted in the same buffer plus 200 mM imidazole and concentrated using an Amicon 30 kDa cut-off spin concentrator for addition to the reconstituted high-density lipoprotein particles (rHDL) reconstitution mixture.
Receptor reconstitution into rHDL particles. Reconstitutions were performed as described 32 , with the amount of receptor added never exceeding 20% of the total reaction volume. For samples that contained Gs, the purified heterotrimer was added to the preformed β 2 AR-rHDL particles, incubated for 2 h at 4 °C, and BioBeads (Bio-Rad) were used to remove the added detergent. Nucleotide-free Gs•β 2 AR complex was prepared by incubating β 2 AR-Gs-rHDL particles with apyrase in the presence of 1 mM MgCl 2 for 30 min at room temperature, or alternatively, 2 h at 4 °C. If needed, the sample was passed through a Superdex 200 gel filtration column to remove free nucleotide and apyrase.
Radioligand association experiments using rHDL particles. All assays were performed in Tris-buffered saline (TBS; 25 mM Tris-HCl, pH 7.4, 136 mM NaCl, 2.7 mM KCl) with a final concentration of 0.05% w/v bovine serum albumin (BSA). Reaction components were mixed and pre-incubated at room temperature (see later) before the addition of radioligand to initiate the association time course.
Aliquots were withdrawn at the indicated times and filtered over Whatman GF/B filters pre-soaked in 0.3% w/v polyethyleneimine. Filters were washed with icecold TBS, dried, and subjected to liquid scintillation counting on a TopCount NXT (Perkin-Elmer For association experiments, gel-filtered samples of apyrase-treated Gs•β 2 AR-rHDL particles were incubated with 5 nM [ 3 H]DHAP to bind any receptor that was not complexed with Gs. The experiment was started by adding varying amounts of either GDP or GTPγS. For 'equilibrium' binding experiments, samples were incubated with all the indicated components at room temperature for 90 min before filtration. Non-specific binding was determined in the presence of 10 μM (+/−)-propranolol. To a first approximation, the rapid binding event suggests that the complex is empty of nucleotide, based on the limited temporal resolution of this mixing and filtration technique. 
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Extended Data Figure 5 | Y308A mutation abolishes the rate-slowing effects of Nb80. a, b, Time course of [ 3 H]DHAP binding to wild-type (WT) β 2 AR (a) or β 2 AR(Y308A) (b) after pre-incubation of receptor with Nb80. Nb80 significantly slowed [ 3 H]DHAP association to wildtype β 2 AR (−Nb80 observed rate constant, k obs = 0.45 ± 0.05 min −1 or association half-time, t ½ = 1.5 ± 0.2 min, +Nb80 k obs = 0.20 ± 0.03 min −1 or t ½ = 3.5 ± 0.5 min; P = 0.011 by an unpaired two-tailed t-test), but less effectively slowed [ 3 H]DHAP association to β 2 AR(Y308A) (−Nb80 k obs = 0.50 ± 0.06 min −1 or t ½ = 1.4 ± 0.2 min; +Nb80 k obs = 0.32 ± 0.01 min −1 or t ½ = 2.2 ± 0.1 min; P = 0.05 by an unpaired twotailed t-test. All data are shown as mean ± s.e.m. from n = 4 (−Nb80) or n = 3 (+Nb80) independent experiments performed in duplicate. c, d, Time course of [ 3 H]formoterol binding to wild-type β 2 AR (c) or β 2 AR(Y308A) (d) after pre-incubation of receptor with Nb80. Nb80 slowed [ 3 H]formoterol association to wild-type β 2 AR (0.1 μM Nb80 k obs = 0.68 ± 0.13 min −1 or t ½ = 1.0 ± 0.2 min, 10 μM Nb80 k obs = 0.27 ± 0.05 min −1 or t ½ = 2.6 ± 0.5 min; P = 0.031 by an unpaired two-tailed t-test). However, with β 2 AR(Y308A), Nb80 had little effect on the observed association rate constant but enhanced the amount of [ 3 H]formoterol bound (0.1 μM Nb80 k obs = 0.37 ± 0.11 min −1 or t ½ = 1.9 ± 0.6 min with a plateau of 10.1 ± 0.8 fmol, 10 μM Nb80 k obs = 0.53 ± 0.13 min −1 or t ½ = 1.3 ± 0.4 min with a plateau of 21.3 ± 1.2 fmol; unpaired two-tailed t-test of the k obs values showed P = 0.4). All data are shown as mean ± s.e.m. from n = 4 independent experiments performed in duplicate.
